Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria-Reference-Cited by-同舟云学术

Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria

Published:2008-07 Issue:2 Volume:142 Page:263-272
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Schubert Jrg,Hillmen Peter,Rth Alexander,Young Neal S.,Elebute Modupe O.,Szer Jeffrey,Gianfaldoni Giacomo,Soci Grard,Browne Paul,Geller Robert,Rother Russell P.,Muus Petra

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07183.x/fullpdf

Reference24 articles.

1. Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: a tool for measuring the extent of the PNH clone;Alfinito;Leukemia,1996

2. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene;Bessler;EMBO Journal,1994

3. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): Phase III TRIUMPH study results;Brodsky;Blood,2006

4. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria;Brodsky;Blood,2008

5. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue;Caocci;Leukemia Research,2007

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study;Advances in Therapy;2024-04-04

2. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria;Annals of Hematology;2023-10-07

3. Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data;European Journal of Haematology;2023-04-19

4. Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis;Therapeutic Advances in Hematology;2023-01

5. Les inhibiteurs du complément : une vue d’ensemble;La Revue de Médecine Interne;2022-12